Biotech News Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: fred hayes	4/22/2008 10:25:49 AM
	Read Replies (1) of 7143

Here comes another antipsychotic shot on goal: ---------------------------------------------------- Tuesday, April 22, 2008 - 6:28 AM PDT FDA clears ARYx antipsychotic for clinical testingSilicon Valley / San Jose Business Journal The Food and Drug Administration cleared a new antipsychotic from ARYx Therapeutics Inc. for clinical testing, the company said Tuesday. Fremont-based ARYx (NASDAQ:ARYX) said the drug is designed to treat schizophrenia and other psychiatric disorders. "ATI-9242 is an innovative new compound with potential for significant utility in the treatment of psychiatric disorders," said CEO Dr. Paul Goddard. "I am excited to have initiated human studies ahead of schedule, and I am appreciative of the pioneering work done by ARYx's research team, led by our Chief Scientific Officer, Dr. Pascal Druzgala, to enable rapid advancement of this compound into the clinic." ARYx expects to complete the Phase 1 study by the end of 2008.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next